Zevra Therapeutics (NASDAQ:ZVRA) PT Raised to $20.00

Zevra Therapeutics (NASDAQ:ZVRA) had its price target lifted by investment analysts at HC Wainwright from $18.00 to $20.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 148.45% from the stock’s previous close.

ZVRA has been the topic of a number of other reports. Canaccord Genuity Group decreased their target price on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 14th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $21.25.

Zevra Therapeutics Stock Up 0.4 %

Shares of ZVRA stock traded up $0.03 during trading hours on Friday, hitting $8.05. 2,662,908 shares of the company were exchanged, compared to its average volume of 453,451. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.95. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. The business has a 50 day moving average of $7.00 and a two-hundred day moving average of $5.70. The company has a market capitalization of $336.92 million, a PE ratio of -5.98 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The business had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. During the same quarter last year, the business earned ($0.15) earnings per share. Analysts anticipate that Zevra Therapeutics will post -1.58 earnings per share for the current fiscal year.

Insider Buying and Selling at Zevra Therapeutics

In related news, Director John B. Bode acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, July 12th. The shares were bought at an average cost of $5.87 per share, with a total value of $58,700.00. Following the completion of the purchase, the director now directly owns 30,000 shares in the company, valued at $176,100. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders acquired 22,000 shares of company stock worth $140,340. 2.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD purchased a new stake in shares of Zevra Therapeutics in the first quarter worth approximately $64,000. The Manufacturers Life Insurance Company raised its holdings in shares of Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares during the last quarter. Focus Financial Network Inc. ADV purchased a new position in shares of Zevra Therapeutics in the 4th quarter worth approximately $141,000. Virtu Financial LLC purchased a new position in Zevra Therapeutics in the fourth quarter worth $177,000. Finally, Jacobs Levy Equity Management Inc. grew its stake in Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after purchasing an additional 17,557 shares during the period. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.